Cerbios header

Cerbios header

X

[{"orgOrder":0,"company":"AbCellera","sponsor":"Kodiak Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AbCellera and Kodiak Sciences Enter Second Antibody Discovery Collaboration for Ophthalmology Targets","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Discovery Platform","country":"CANADA","productType":"Large molecule","productStatus":"Undisclosed","date":"October 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"AbCellera"},{"orgOrder":0,"company":"Aavnergene","sponsor":"Neurophth Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Neurophth and AAVnerGene Enter Strategic AAV Capsids Partnership for Next-Generation Ophthalmic Gene Therapy","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Aavnergene"},{"orgOrder":0,"company":"Beam Therapeutics","sponsor":"Apellis Pharmaceuticals","pharmaFlowCategory":"D","amount":"$75.0 million","upfrontCash":"$50.0 million","newsHeadline":"Apellis and Beam Therapeutics Enter Research Collaboration to Apply Base Editing to Discover Novel Therapies for Complement-Driven Diseases","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Beam Therapeutics"},{"orgOrder":0,"company":"Evotec","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Evotec Enters iPSC-Based Drug Discovery Partnership with Boehringer Ingelheim in Ophthalmology","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Discovery Platform","country":"GERMANY","productType":"Small molecule","productStatus":"Undisclosed","date":"January 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Evotec"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

Company

filter

Sponsor

filter

Country

filter

Product Type

filter

News Type

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

Evotec

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Evotec Enters iPSC-Based Drug Discovery Partnership with Boehringer Ingelheim in Ophthalmology

Details:

Through phenotypic screening of human iPSC-derived cells, supported by Evotec’s PanOmics platform, Evotec will identify small molecules able to modulate disease phenotypes, and then validate the underlying promising targets for potential therapeutic interventions.

Lead Product(s): Undisclosed

Therapeutic Area: Ophthalmology Product Name: Undisclosed

Highest Development Status: Discovery Platform Product Type: Small molecule

Partner/Sponsor/Collaborator: Boehringer Ingelheim GmbH

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Partnership January 25, 2022

ASK
US

Upload
your Pipeline Activity

Beam Therapeutics

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Apellis and Beam Therapeutics Enter Research Collaboration to Apply Base Editing to Discover Novel Therapies for Complement-Driven Diseases

Details:

Collaboration combines Apellis’ expertise in complement with Beam’s proprietary base editing platform. Companies will collaborate on six research programs directed to tissues modulated by the complement system, including the eye, liver, and brain.

Lead Product(s): Undisclosed

Therapeutic Area: Ophthalmology Product Name: Undisclosed

Highest Development Status: Discovery Platform Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Apellis Pharmaceuticals

Deal Size: $75.0 million Upfront Cash: $50.0 million

Deal Type: Collaboration June 30, 2021

ASK
US

Upload
your Pipeline Activity

Aavnergene

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Neurophth and AAVnerGene Enter Strategic AAV Capsids Partnership for Next-Generation Ophthalmic Gene Therapy

Details:

Subject to the terms of the agreement, Neurophth will make an initial cash payment to AAVnerGene to test ~100 AAV capsids. Within 6-12 months upon receiving the AAV capsids, Neurophth is responsible for completing the preclinical studies on these capsids.

Lead Product(s): AAV capsids-gene therapy

Therapeutic Area: Ophthalmology Product Name: Undisclosed

Highest Development Status: Discovery Platform Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Neurophth Therapeutics

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Partnership January 19, 2021

ASK
US

Upload
your Pipeline Activity

AbCellera

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

AbCellera and Kodiak Sciences Enter Second Antibody Discovery Collaboration for Ophthalmology Targets

Details:

AbCellera will use its full stack, AI-powered antibody discovery technology to discover and identify a large panel of antibodies against new targets designated by Kodiak.

Lead Product(s): Antibodies

Therapeutic Area: Ophthalmology Product Name: Undisclosed

Highest Development Status: Discovery Platform Product Type: Large molecule

Partner/Sponsor/Collaborator: Kodiak Sciences

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration October 29, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY